Table 7 Side Effects.
From: Deflazacort for the treatment of Duchenne Dystrophy: A systematic review
Study (Duration of Follow up) | A. Bonifati, 2000 (12 months) | B. Angelini, 1994 (12 months) | F. Angelini, 1998 (12 months) | G. Angelini, 1995 (unclear) | N. Brooke, 1996 (12 months) |
|---|---|---|---|---|---|
Weight Gain | |||||
Mean weight increase as a percentage of initial weight | DFZ: 9% Pred: 21.3 % p < 0.05 | Not significant. No numeric values given. | Reported as minimal. No numeric values given. | Not significantly different from the placebo. No numeric values given. | DFZ low: 16.8% DFZ high: 18.3% Pred: 26.7% p < 0.01 |
Others | |||||
Fractures or osteoporosis | N = 1 (DFZ) | N = 1 (DFZ) | Reported as minimal. No numeric values. | - | - |
Hirsutism | - | N = 3 (total) | - | - | - |
Cushingoid | - | N = 2 (total) | - | - | - |
Increased Appetite | - | N = 4 (total) | - | - | - |
Behavior Changes | - | N = 5 (total) | - | - | - |
Cataract | N = 2 (DFZ) N = 1 (Prednisone) | - | Reported as minimal. No numeric values. | - | - |